Serina Therapeutics Profit Margin

The latest profit margin for SER is -16583.08% as of March 2026. That compares with -1841.18% in the prior-year period — down 800.7% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Serina Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SER's profit margin moved from -1841.18% to -16583.08% — a 800.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Serina Therapeutics's valuation or profitability profile.

Against Healthcare companies, SER currently prints -16583.08% for profit margin, while the sector average sits near 14.34%. That is roughly 115703.6% below the sector mean. Large gaps often invite a closer look at Serina Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Serina Therapeutics converts resources into returns. At -16583.08%, SER may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1841.18% in the prior-year period — down 800.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SER's profit margin (-16583.08%), review year-over-year change from -1841.18%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.